Dentsply Sirona Q2 adjusted EPS of $0.52 beats $0.36 consensus; guidance maintained
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-09. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Operating cost controls and Wellspect revenue resilience offset dental equipment softness to protect XRAY's FY2026 EPS range of $1.40-$1.50.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factDentsply Sirona reported Q2 adjusted EPS of $0.52, beating consensus expectations of $0.36. |
| What else was confirmed? | Reported factNet revenues fell 4.1% year-over-year during the quarter. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for XRAY yet — this is the next research task. |
| What would change the assessment? | UnknownXRAY second-half dental margin performance — Sell-side estimate revisions following Q2 EPS outperformance |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Dentsply Sirona reported Q2 adjusted EPS of $0.52, beating consensus expectations of $0.36.
- · Net revenues fell 4.1% year-over-year during the quarter.
- · Wellspect Healthcare segment revenue grew 7.1% year-over-year.
- · Management maintained full-year 2026 sales guidance of $3.5 billion to $3.6 billion and adjusted EPS guidance of $1.40 to $1.50.
Public research record
Research framework · page evidenceCompleted event assessment
operating margin preservation lifting adjusted earnings realization
| Type | Claim | Scope |
|---|---|---|
| Assumption | Dentsply Sirona reported Q2 adjusted EPS of $0.52, beating consensus expectations of $0.36. | 2026-09-09 |
| Interpretation | operating margin preservation lifting adjusted earnings realization | XRAY |
Countercase, invalidators, and sources
Consumables demand acceleration offsets equipment softness, lifting full-year EPS toward the $1.50 high end.
- · XRAY second-half dental margin performance — Sell-side estimate revisions following Q2 EPS outperformance
- XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure · 2026-09-08
What remains unresolved
- Base path
- XRAY tracks within its $3.5B-$3.6B sales guidance with steady Wellspect contribution.
- Adverse path
- Dental practice capital expenditure delays exacerbate equipment segment contraction.
- Supportive path
- Consumables demand acceleration offsets equipment softness, lifting full-year EPS toward the $1.50 high end.
- · XRAY second-half dental margin performance — Sell-side estimate revisions following Q2 EPS outperformancethis week
Evidence
- XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure2026-09-08
“DENTSPLY SIRONA (XRAY) exceeded Q2 earnings and revenue estimates with adjusted EPS of 52 cents versus 36 cents consensus, though revenues fell 4.1% year-over-year. The company maintained full-year 2026 guidance of $3.5-3.6B in sales and $1.40-1.50 adjusted EPS.”
Supports: DENTSPLY SIRONA reported Q2 adjusted EPS of $0.52 vs $0.36 consensus, revenue down 4.1%, Wellspect up 7.1%, and reaffirmed FY2026 guidance.